GlobeNewswire

SmartCash Highlights 2018 Initiatives to Accelerate Global Adoption, Recaps Key Achievements

Dela

Roadmap milestones focus on further scalability, merchant adoption, security and support

 

NEW YORK, April 26, 2018 (GLOBE NEWSWIRE) -- via NetworkWire -- SmartCash, a community governance, cooperation and growth focused crypto-asset created via blockchain technology, today provides an overview of its recent achievements and ambitions for the year ahead.

Self-funded, Merchant-Centric, Community-Driven and Easy to Use

Recent accomplishments have positioned SmartCash to become the ideal choice for making payments anywhere in the world by introducing the following:

  • Username-based addresses vs. highly complex addresses of Bitcoin and other cryptocurrencies
  • Self-funded model to ensure continual development and outreach
  • Transaction fees of less than 1/10th a cent
  • Advanced governance system to give every SmartCash holder a voice
  • SmartNodes to enable InstantPay and other future services
  • Easy-to-use web wallet and mobile app

To learn more about SmartCash's innovations, visit https://smartcash.cc/

2018 Initiatives to Accelerate Growth of SmartCash Community

Following the completion of prior roadmap milestones, the global SmartCash developer team has laid out ten new road map milestones to accomplish by the end of this year. These initiatives emphasize the core mission of SmartCash to provide a viable, fungible, fast, merchant-oriented, user-friendly and community-driven crypto with a decentralized governance system.

SmartCard

A revolutionary payment system that improves upon and/or eliminates the present limitations of conventional payment methods with the ability to setup a new merchant in minutes, transaction confirmation in fractions of a second, usability where traditional banking services are unavailable, and immeasurable savings for merchants due to essentially non-existent transaction fees.

Send-to-Email Functionality

Sending SmartCash to another person or business will be easier than ever with the ability to send SmartCash directly to anyone's email address, even if they don't have an existing web wallet account.

Adaptive Blocks

Blocks will increase in size based on the average block size to enable the maximum transactions per second, ensuring optimal scalability as additional individuals and merchants use SmartCash.

24-hour Support Center

The SmartCash support team is ramping up to a round-the-clock support center that will help new merchants accept SmartCash while also giving direction to new users.

Digital Wallet Innovations, Core Upgrades, and More

Other items on the roadmap include introducing an electrum wallet to eliminate the need to wait for the blockchain to download, launching a native mobile wallet with multicurrency trading ability, upgrading the block explorer for greater accuracy and improved interface, and more.

To view a visual roadmap and current progress, visit https://smartcash.cc/roadmap/

Engagement of Media Relations Firm

To increase visibility of prior accomplishments and future announcements, the SmartCash community has voted to engage Blockchain Relations. Officially contracted on April 1, 2018, Blockchain Relations will utilize multiple communication channels and platforms to ensure ongoing media coverage via syndicated articles and editorials, journalist outreach, a SmartCash-branded news portal, and various engagement initiatives.

About SmartCash

SmartCash (SMART) is a blockchain-based crypto that sets itself apart with community governance, a self-funded community treasury, and mining accessibility to standard PCs. With emphasis on community involvement and merchant adoption, SmartCash aims to create the most nimble and fastest-growing crypto.

To learn more about SmartCash, visit: https://smartcash.cc/

Interactive Flipbook

To learn more about SmartCash via an interactive flipbook, visit http://smartcash.blockchainnewssource.com/flipbook/

Engage with the SmartCash Community

Discord chat via https://discord.gg/BDUh8jr 
Telegram chat via http://bit.do/smartcash 
Twitter social media via https://www.facebook.com/scashofficial/ 
Facebook social media via https://www.facebook.com/scashofficial 
YouTube social media via https://www.youtube.com/channel/UCzwZxu6BtWcRiQXdPqNeB5Q/featured

SmartCash Contact
SmartCash
https://smartcash.cc/ 
hello@smartcash.cc

Blockchain Relations Contact
Blockchain Relations
http://www.blockchainrelations.io
614-465-6025
press@blockchainrelations.io




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: SmartCash via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Upcoming Conferences in March and April22.3.2019 08:00:00 CETPressmeddelande

Press Release 22 March 2019 Immunicum AB (publ) Announces Upcoming Conferences in March and April Immunicum AB (publ; IMMU.ST) announced today that members of the management team will attend and present at upcoming conferences in March and April. BIO-Europe Spring Date: March 25-27, 2019 Venue: Messe Wien Exhibition and Congress Center, Vienna, Austria Participant: Sijme Zeilemaker China Focus @ Europe Vienna Date: March 27, 2019 Panel Time/Session: 16.10 - 17.00, Panel 4: Partnering Opportunities with Chinese Pharma Venue: Hilton Vienna Danube Waterfront, Vienna, Austria Participant: Carlos de Sousa Swedish American Life Science Summit 2019 Date: April 9-10, 2019 Presentation Date: Wednesday, April 10, 2019 Venue: House of Sweden, 2900 K St. NW, Washington D.C. 20008 Participant: Carlos de Sousa For more information, please contact: Carlos de Sousa, CEO, Immunicum Telephone: +46 8 732 8400 E-mail: info@immunicum.com Michaela Gertz, CFO, Immunicum Telephone: +46 70 926 17 75 E-mail: ir

Immunicum AB (publ) meddelar kommande konferenser i mars och april22.3.2019 08:00:00 CETPressmeddelande

Pressmeddelande 22 mars 2019 Immunicum AB (publ) meddelar kommande konferenser i mars och april Immunicum AB (publ; IMMU.ST) meddelar idag att medlemmar av ledningsgruppen kommer att delta och presentera vid kommande konferenser i mars och april. BIO-Europe Spring Datum: 25-27 mars 2019 Plats: Messe Wien Exhibition and Congress Center, Wien, Österrike Deltagare: Sijme Zeilemaker China Focus @ Europe Vienna Datum: 27 mars 2019 Paneltid/Sessionstid: 16.10 - 17.00, Panel 4: Partnering Opportunities with Chinese Pharma Plats: Hilton Vienna Danube Waterfront, Wien, Österrike Deltagare: Carlos de Sousa Swedish American Life Science Summit 2019 Datum: 9-10 april 2019 Presentationsdatum: Onsdagen 10 april 2019 Plats: House of Sweden, 2900 K St. NW, Washington D.C. 20008 Deltagare: Carlos de Sousa För ytterligare information kontakta: Carlos de Sousa, VD, Immunicum Telefon: +46 8 732 8400 E-post: info@immunicum.com Michaela Gertz, Finanschef, Immunicum Telefon: +46 (0) 70 926 17 75 E-post: ir@i

Karolinska Development's portfolio company Promimic announces partnership with Onkos Surgical15.3.2019 08:45:00 CETPressmeddelande

STOCKHOLM, March 15, 2019. Karolinska Development's portfolio company Promimic announces a new partnership with the U.S company Onkos Surgical® to commercialize Promimic's proprietary Hydroxyapatite (HA) Surface Technologies in Limb Salvage Surgery. Promimic develops and markets products within nano-materials for innovative surface treatments and has developed the HA nano Surface that is clinically proven to speed up and improve the anchoring of implants in bone. The innovative technology is already licensed to several dental implant companies. The partnership with Onkos Surgical®, a U.S company addressing the clinical challenges associated with tumor surgery, represents an important step into the orthopaedic space. The partnership will focus on combining Promimic's HA nano Surface Technology with Onkos Surgical®'s ELEOS Limb Salvage Portfolio. Implant failure due to aseptic loosening remains one of the key challenges associated with limb salvage surgery. With HA nano Surface, Onkos Su

Karolinska Development's portfolio company Promimic announces partnership with Onkos Surgical15.3.2019 08:45:00 CETPressmeddelande

STOCKHOLM, March 15, 2019. Karolinska Development's portfolio company Promimic announces a new partnership with the U.S company Onkos Surgical® to commercialize Promimic's proprietary Hydroxyapatite (HA) Surface Technologies in Limb Salvage Surgery. Promimic develops and markets products within nano-materials for innovative surface treatments and has developed the HA nano Surface that is clinically proven to speed up and improve the anchoring of implants in bone. The innovative technology is already licensed to several dental implant companies. The partnership with Onkos Surgical®, a U.S company addressing the clinical challenges associated with tumor surgery, represents an important step into the orthopaedic space. The partnership will focus on combining Promimic's HA nano Surface Technology with Onkos Surgical®'s ELEOS Limb Salvage Portfolio. Implant failure due to aseptic loosening remains one of the key challenges associated with limb salvage surgery. With HA nano Surface, Onkos Su

Karolinska Development's portfolio company Forendo Pharma announces positive results from a Phase Ia study of FOR 62197.3.2019 09:00:00 CETPressmeddelande

STOCKHOLM, March 7, 2019. Karolinska Development's portfolio company Forendo Pharma today announces positive results from a Phase Ia study with the drug candidate FOR 6219 for the treatment of endometriosis. The results found FOR 6219 to be safe and well tolerated, with good pharmacokinetics at the doses tested. The randomized, double blind, placebo controlled Phase Ia study investigated the safety, tolerability, food effect and pharmacokinetics of single and multiple ascending oral doses of FOR 6219 in 36 healthy postmenopausal women. In the study, single doses of FOR 6219 from 2 mg up to 175 mg and multiple doses up to 150 mg twice daily for ten days were found to be safe and well tolerated. The pharmacokinetic results showed a dose proportionate exposure and no significant food effect. The safety and pharmacokinetic profile of FOR 6219 supports the initiation of a Phase Ib clinical trial in healthy premenopausal women with the aim to demonstrate Proof of Mechanism. The selective abi

Karolinska Development's portfolio company Forendo Pharma announces positive results from a Phase Ia study of FOR 62197.3.2019 09:00:00 CETPressmeddelande

STOCKHOLM, March 7, 2019. Karolinska Development's portfolio company Forendo Pharma today announces positive results from a Phase Ia study with the drug candidate FOR 6219 for the treatment of endometriosis. The results found FOR 6219 to be safe and well tolerated, with good pharmacokinetics at the doses tested. The randomized, double blind, placebo controlled Phase Ia study investigated the safety, tolerability, food effect and pharmacokinetics of single and multiple ascending oral doses of FOR 6219 in 36 healthy postmenopausal women. In the study, single doses of FOR 6219 from 2 mg up to 175 mg and multiple doses up to 150 mg twice daily for ten days were found to be safe and well tolerated. The pharmacokinetic results showed a dose proportionate exposure and no significant food effect. The safety and pharmacokinetic profile of FOR 6219 supports the initiation of a Phase Ib clinical trial in healthy premenopausal women with the aim to demonstrate Proof of Mechanism. The selective abi

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum